F 522 | CAS# 25134-54-7 | xxxx

MedKoo Cat#: 581128 | Name: F 522

Description:

WARNING: This product is for research use only, not for human or veterinary use.

F 522 is also kown as DA-3031. DA-3031 is a newly developed pegylated filgrastim, a recombinant human granulocyte colony-stimulating factor, that is expected to have an extended duration of action compared with non-modified filgrastim. was developed for prophylactic use in breast cancer.

Chemical Structure

F 522

CAS#25134-54-7

Theoretical Analysis

MedKoo Cat#: 581128

Name: F 522

CAS#: 25134-54-7

Chemical Formula: C10H19NO2

Exact Mass: 185.1416

Molecular Weight: 185.27

Elemental Analysis: C, 64.83; H, 10.34; N, 7.56; O, 17.27

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

F 522; DA 1701; DA 3023; DA 3031;F522; F-522; Sumiepoch F 522;

IUPAC/Chemical Name

2-(dimethylamino)ethyl methacrylate compound with ethene (1:1)

InChi Key

PNMYDOBPCBCQIA-UHFFFAOYSA-N

InChi Code

InChI=1S/C8H15NO2.C2H4/c1-7(2)8(10)11-6-5-9(3)4;1-2/h1,5-6H2,2-4H3;1-2H2

SMILES Code

C(C(=C)C)(=O)OCCN(C)C.C=C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 185.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ahn LY, Shin KH, Lim KS, Kim TE, Jeon H, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. Relationship between absolute neutrophil count profiles and pharmacokinetics of DA-3031, a pegylated granulocyte colony-stimulating factor (pegylated-G-CSF): a dose block-randomized, double-blind, dose-escalation study in healthy subjects. Clin Drug Investig. 2013 Nov;33(11):817-24. PubMed PMID: 24078278. 2: Park KH, Sohn JH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Hong DS, Park S, Shin SH, Kwon HC, Seo JH. A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer. Invest New Drugs. 2013 Oct;31(5):1300-6. doi: 10.1007/s10637-013-9973-4. Epub 2013 May 16. PubMed PMID: 23677653. 3: Wadhwa M, Bird C, Dougall T, Rigsby P, Bristow A, Thorpe R; participants of the study. Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): report of an international collaborative study. J Immunol Methods. 2015 Jan;416:17-28. doi: 10.1016/j.jim.2014.10.005. Epub 2014 Oct 25. PubMed PMID: 25450254; PubMed Central PMCID: PMC4334095. 4: Park KH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Park S, Lee SI, Jung KH, Kim YS, Seo JH. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer. Support Care Cancer. 2017 Feb;25(2):505-511. doi: 10.1007/s00520-016-3429-2. Epub 2016 Oct 6. PubMed PMID: 27709313. 5: Kam G, Yiu R, Loh Y, Ang AL, Yueh LL, Goh YT, Wong GC. Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy. Support Care Cancer. 2015 Mar;23(3):643-9. doi: 10.1007/s00520-014-2417-7. Epub 2014 Aug 27. PubMed PMID: 25160495. 6: Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Zou B, Brusko TM, Hulme MA, Wasserfall CH, Mathews CE, Atkinson MA, Schatz DA. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. J Clin Invest. 2015 Jan;125(1):448-55. doi: 10.1172/JCI78492. Epub 2014 Dec 15. PubMed PMID: 25500887; PubMed Central PMCID: PMC4382237. 7: Skyler JS. Immune therapy for treating type 1 diabetes: challenging existing paradigms. J Clin Invest. 2015 Jan;125(1):94-6. doi: 10.1172/JCI79190. Epub 2014 Dec 15. PubMed PMID: 25500880; PubMed Central PMCID: PMC4382231. 8: Zeynalova S, Ziepert M, Scholz M, Schirm S, Zwick C, Pfreundschuh M, Loeffler M; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Comparison and modelling of pegylated or unpegylated G-CSF schedules in CHOP-14 regimen of elderly patients with aggressive B-cell lymphoma. Ann Hematol. 2013 Dec;92(12):1641-52. doi: 10.1007/s00277-013-1842-x. Epub 2013 Jul 28. PubMed PMID: 23892922. 9: Kang JS, Lee KC. In vivo pharmacokinetics and pharmacodynamics of positional isomers of mono-PEGylated recombinant human granulocyte colony stimulating factor in rats. Biol Pharm Bull. 2013;36(7):1146-51. PubMed PMID: 23811564. 10: Plett PA, Chua HL, Sampson CH, Katz BP, Fam CM, Anderson LJ, Cox GN, Orschell CM. PEGylated G-CSF (BBT-015), GM-CSF (BBT-007), and IL-11 (BBT-059) analogs enhance survival and hematopoietic cell recovery in a mouse model of the hematopoietic syndrome of the acute radiation syndrome. Health Phys. 2014 Jan;106(1):7-20. doi: 10.1097/HP.0b013e3182a4dd4e. PubMed PMID: 24276546; PubMed Central PMCID: PMC3843149.